Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Summary

ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. The population will consist of adults with PD-L1 positive recurrent or metastatic HNSCC.

Timeline

Start

2019-08-26

Primary completion

2021-05-10

Completion

2021-06-10

Publications

• Gogoi H, Mansouri S, Jin L. The Age of Cyclic Dinucleotide Vaccine Adjuvants. Vaccines (Basel). 2020 Aug 13;8(3):453. doi: 10.3390/vaccines8030453.

Drugs

Indications